Remdesivir linked to lower COVID-19 mortalityHospitalized COVID-19 patients who were treated with remdesivir within 2 days of admission had lower mortality rates than their matched cohort, according to a study today in Clinical Infectious Diseases.
The observational cohort consisted of US adults hospitalized with COVID-19 from August to November 2020; 28,855 received remdesivir and 16,887 did not.About 10.6% of patients who received remdesivir died within 14 days, and 15.4% died within 28 days, while those who didn't receive remdesivir had 14- and 28-day mortality rates of 15.4% and 19.1%, respectively.
The researchers estimate that the antiviral drug reduces risk of death by 24% for 14-day mortality and by 11% at 28 days (95% CIs, 0.70 to